Retraction Note: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment

Affiliations

• ¹ Department of Urology, Keio University School of Medicine, Tokyo, Japan.
• ² Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
• ³ National Hospital Organization, Higashi Nagoya National Hospital, Nagoya, Japan.
• ⁴ Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd., 2-4-9 Umeda, Kita-Ku, Osaka, 530-0001, Japan.
• ⁵ Product Development, Bayer Yakuhin, Ltd., Osaka, Japan.
• ⁶ Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd., 2-4-9 Umeda, Kita-Ku, Osaka, 530-0001, Japan. yutaka.okayama@bayer.com.